• About us
• Contact

Advertisement

Organisation › Details

Vivoryon (Group)

Headquartered in Halle (Saale), Germany, Vivoryon Therapeutics AG (Euronext Amsterdam: currently PBD, to be changed to VVY) is a clinical stage precision medicine company focused on bringing first-in-class therapies to patients suffering from age-related diseases. The company has a successful track record in bringing drugs targeted to post-translational modifying enzymes to the market. Current projects are focusing on the two isoenzymes of Glutaminyl cyclase, QPCT and QPCTL. QPCT is the crucial enzyme for the generation of highly neurotoxic pyroglutamate species of Abeta. Its inhibition by Vivoryon’s lead molecule PQ912, has successfully completed a Phase 2a (SAPHIR) study and the Company has initiated a Phase 2b core program for the treatment of Alzheimer’s disease (AD). Whereas QPCTL has been identified as a potential target in cancer therapy. Blocking the enzymatic function of QPTCL by small molecule inhibitors is a novel therapeutic approach to silence the CD47/SIRP? signal in cancer immunotherapy. Vivoryon has a unique and exceptionally strong patent position on QPCT and QPCTL inhibitors. *

 

	Start	2019-06-11 renamed
	Predecessor	Probiodrug (Group)
	Industry	drug development technology
	Industry 2	QC inhibitor (glutam(in)yl cyclase inhibitor)
	Person	Dauer, Ulrich (Probiodrug 201805– CEO before Omeicos + Activaero + 4SC + Tripos)
	Person 2	Schäffer, Michael (Probiodrug 201810– CBO joined 201808 as EVP Business + Strategy before Crelux + Sireen)
	Region	Halle (Saale)
	Country	Germany
	Street	22 Weinbergweg
	City	06120 Halle (Saale)
	Tel	+49-345-55599-00
		Address record changed: 2024-01-05
Basic data	Employees	B: 11 to 50 (2019-06-30)
	Currency	EUR
	Annual sales	44,000 (operating income (2015) 2015-12-31)
	Profit	-13,891,000 (2016-12-31)
	Cash	9,300,000 (2018-03-31)
		* Document for »About Section«: Probiodrug AG. (6/12/19). "Press Release: Probiodrug AG Becomes Vivoryon Therapeutics AG". Halle (Saale).
		Record changed: 2023-12-30

Advertisement

More documents for Vivoryon (Group)

• [1] Vivoryon Therapeutics N.V.. (6/29/21). "Press Release: Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer's Disease in Greater China". Halle...
• [2] Vivoryon Therapeutics AG. (1/14/20). "Press Release: Vivoryon Therapeutics and Nordic Bioscience Enter Research and Development Collaboration". Halle (Saale) & Herlev....
• [3] Vivoryon Therapeutics AG. (10/8/19). "Press Release: Vivoryon Therapeutics AG Launches Rights Offering to Fund its Phase 2b Clinical Development Program in Alzheimer’s Disease with Strong Commitments [Not for US, et al.]". Halle (Saale)....
• [4] Vivoryon Therapeutics AG. (8/29/19). "Press Release: Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update". Halle (Saale)....
• [5] MorphoSys AG. (7/8/19). "Press Release: MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology". Planegg & Halle (Saale)....
• [6] Probiodrug AG. (6/12/19). "Press Release: Probiodrug AG Becomes Vivoryon Therapeutics AG". Halle (Saale)....
• [7] Probiodrug AG. (4/9/19). "Press Release: Probiodrug Raises EUR 8.2 Million from Investors in Successful Private Placement of New Shares [NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA]". Halle (Saale)....
• [8] Probiodrug AG. (4/4/19). "Press Release: Probiodrug AG Has Mandated Oddo Seydler Bank AG as Designated Sponsor. The Shares Are Trading on XETRA, the Electronic Trading Platform of Deutsche Börse". Halle (Saale)....
• [9] Probiodrug AG. (3/28/19). "Press Release: Probiodrug Reports Full Year 2018 Financial Results". Halle (Saale)....
• [10] Probiodrug AG. (10/5/18). "Press Release: Probiodrug Reports Management Changes". Halle (Saale)....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.